Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results
Ongoing INOpulse® REBUILD Phase 3 trial enrollment completion expected in the first quarter of 2023, with pivotal top-line data readout...
Clinical Trial
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results
– Cash Position of $21.3 Million as of September 30, 2022 – – Hosting Phase 3 REGAL Study Update Webcast...
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
- SHINE Alzheimer’s Trial Expands to European Sites - - SEQUEL Alzheimer’s Trial Awarded Additional NIA Grant to Complete -...
Immutep Receives Australian R&D Tax Incentive
Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ:...
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Continued execution to advance exebacase and CF-370 into new clinical studiesYONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation...
Revolo Biotherapeutics to Present at TIDES Europe 2022
NEW ORLEANS and LONDON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies...
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
Financing led by Wellington Management with participation from other leading healthcare fundsCARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX...
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update
NORCROSS, Ga., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results
-- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial...
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial of sonelokimab in Hidradenitis Suppurativa...
IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update
Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered...
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH SAN FRANCISCO, Calif., Nov. 14,...
Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million...
Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
DARE-VVA1 Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Supporting Ongoing Development Investigational...
PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates
PGN-EDO53 NHP Exon Skipping, PGN-EDO45 and PGN-EDO44 Exon Skipping in Wild-Type Human Myoblasts High levels of exon skipping were observed...
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results
-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial...
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor) Company to reprioritize...
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
Completed enrollment in the Phase 1 study with novel, broad-spectrum antiviral PB2 candidate CC-42344 for the treatment of pandemic and...